» Articles » PMID: 39727630

Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications

Overview
Journal Diseases
Date 2024 Dec 27
PMID 39727630
Authors
Affiliations
Soon will be listed here.
Abstract

Corticosteroids are extensively used in medicine for their powerful anti-inflammatory and immunosuppressive effects. However, their psychiatric side effects-such as mood disturbances, anxiety, and psychosis-are significant yet often underappreciated. This review provides a comprehensive exploration of corticosteroid-induced psychiatric disorders, with a focus on their underlying mechanisms and clinical implications. We examine how corticosteroids influence the hypothalamic-pituitary-adrenal (HPA) axis, leading to the dysregulation of stress responses and alterations in neurotransmitter levels, particularly dopamine, serotonin, and glutamate. These changes are linked to structural abnormalities in key brain areas such as the hippocampus and amygdala, which are implicated in mood and anxiety disorders, psychosis, and conditions like post-traumatic stress disorder (PTSD) and eating disorders. This review highlights the need for healthcare providers to be vigilant in recognizing and managing corticosteroid-induced psychiatric symptoms, especially in vulnerable populations with pre-existing mental health conditions. The complex relationship between corticosteroid type, dose, duration, and mental health outcomes is explored, emphasizing the importance of personalized treatment approaches to mitigate psychiatric risks. Given the widespread use of corticosteroids, there is an urgent need for more focused research on their psychiatric side effects. This review underscores the importance of patient education and careful monitoring to ensure optimal therapeutic outcomes while minimizing mental health risks associated with corticosteroid therapy.

References
1.
Hill A, Spencer-Segal J . Glucocorticoids and the Brain after Critical Illness. Endocrinology. 2021; 162(3). PMC: 7846201. DOI: 10.1210/endocr/bqaa242. View

2.
Alhammadi N, Mohammed Al Oudhah S, Mofareh Asiri M, Alshehri M, Almutairi B, Mohammed Abdullah Thalibah A . Public awareness of side effects of systemic steroids in Asir region, Saudi Arabia. J Family Med Prim Care. 2023; 12(9):1854-1858. PMC: 10657041. DOI: 10.4103/jfmpc.jfmpc_2202_22. View

3.
Kapugi M, Cunningham K . Corticosteroids. Orthop Nurs. 2019; 38(5):336-339. DOI: 10.1097/NOR.0000000000000595. View

4.
Broberg B, Sommer I, Benros M, Glenthoj B, Gasse C, Kohler-Forsberg O . Glucocorticoids and the risk of schizophrenia spectrum disorder in childhood and adolescence - A Danish nationwide study. Schizophr Res. 2018; 199:116-122. DOI: 10.1016/j.schres.2018.03.007. View

5.
Brown E, Chandler P . Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion J Clin Psychiatry. 2004; 3(1):17-21. PMC: 181154. DOI: 10.4088/pcc.v03n0104. View